### EXPORT LICENSE

NRC FORM 250



# United States of America

**Nuclear Regulatory Commission** Washington, D.C. 20555

NRC LICENSE NO.: XMAT448/02

Page 1 of 11

Peter J. Habighorst, Acting Deputy Director

Office of International Programs

DATE OF ISSUANCE: December 31, 2020

NRC DOCKET NO.: 11006349

LICENSE EXPIRES: December 31, 2025

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE		ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
Cambridge Isotope Laboratories, Inc. 50 Frontage Road Andover, MA 01810		See following page(s)
Attn: Rebecca Dabkowski		
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)		OTHER U.S. PARTY(IES) TO EXPORT
See following page(s)		See following page(s)
\alpha -1.12		
APPLICANT'S REFERENCE: XMAT448		ULTIMATE DESTINATION: India
QUANTITY(IES)	DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)	
	This license is amended to update the list of ultimate foreign consignees by adding 3 additional parties.  The license is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of the original export license XMAT448.	
Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.		THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE Digitally signed by Peter J. Habighorst Habighorst Date: 2020.12.31 07:17:32-05'00'

NAME AND TITLE:

the NRC.

This license is subject to the right of recapture or control

by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now

or hereafter in effect and to all valid rules and regulations of



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)




(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)







(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)




(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)





(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32. India

India

(non-nuclear end use in active pharmaceutical ingredient (API) production)



(non-nuclear end use in active pharmaceutical ingredient (API) production)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)





(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)









(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

### INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):



(for distribution to ultimate consignees)




(for distribution to ultimate consignees)



(for distribution to ultimate consignees)

## INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):



## **OTHER U.S. PARTY(IES) TO EXPORT:**

- Cambridge Isotope Laboratories, Inc. 50 Frontage Road Andover, MA 01810 (supplier/distributors)
- Cambridge Isotope Laboratories, Inc. 6 Highwood Drive Tewksbury, MA 01876

(supplier)

3. Cambridge Isotope Separations 1689 Burnett Drive Xenia, OH 45385

(supplier)